Hepatitis B Reactivation in a US Cohort of People With Human Immunodeficiency Virus and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity
Overall risk of HBV reactivation appears low after switch from HBV-active to non-HBV-active ARV among anti-HBc+ PWH with no prior HBsAg+. Our results inform provider-patient discussion about HBV reactivation risk when considering ARV switching.
Authors
- Amy Weintrob (ORCID: https://orcid.org/0000-0002-4626-5317)
- Rachel Denyer (ORCID: https://orcid.org/0000-0001-9197-1774)
- Debra Benator
- J. K. Lim
- J. Tate
Institutions
- George Washington University (US)
- Yale University (US)
- VA Connecticut Healthcare System (US)
- Washington DC VA Medical Center (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1093/cid/ciag001
- Citations
- 1
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 31.52